Galmed Pharmaceuticals Ltd.
NASDAQTotal Valuation
Galmed Pharmaceuticals Ltd. carries a market capitalization of 2.84M, placing it among publicly traded companies globally. Its enterprise value stands at -12.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.84M |
| Enterprise Value | -12.84M |
Share Statistics
Galmed Pharmaceuticals Ltd. currently has 6.60M shares outstanding.
| Shares Outstanding | 6.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.19 |
| P/FCF Ratio | -0.34 |
| P/OCF Ratio | -0.34 |
Financial Position
Galmed Pharmaceuticals Ltd. maintains a current ratio of 7.71, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.71 |
| Quick Ratio | 7.65 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -64.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Galmed Pharmaceuticals Ltd.'s stock has declined approximately -70.67797% over the past 52 weeks. The 50-day moving average sits at 0.59, while the 200-day moving average is 0.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -70.67797% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.29M, while operating income came in at -9.29M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.29M |
| Pretax Income | -11.11M |
| Net Income | -11.11M |
| EBITDA | -9.29M |
| EBIT | -9.29M |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
Total book value stands at -209.27M, with working capital of 13.95M providing operational flexibility.
| Cash & Cash Equivalents | 15.45M |
| Total Debt | N/A |
| Net Debt | -1.60M |
| Equity (Book Value) | -209.27M |
| Book Value Per Share | -39.24 |
| Working Capital | 13.95M |
Cash Flow
Galmed Pharmaceuticals Ltd. produced -7.68M in operating cash flow over the past twelve months.
| Operating Cash Flow | -7.68M |
| Capital Expenditures | N/A |
| Free Cash Flow | -7.68M |
| FCF Per Share | -1.44 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -287.45 |
| FCF Yield | -294.03 |
Stock Splits
Galmed Pharmaceuticals Ltd.'s most recent stock split took place on August 30, 2024 with a 12:1 split ratio.
| Last Split Date | 8/30/2024 |
| Split Ratio | 12:1 |
Scores
Galmed Pharmaceuticals Ltd. posts an Altman Z-Score of -18.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -18.69 |